Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy

Key Points • Patients without detectable lymphoma at the time of CD19 CAR T-cell therapy had excellent outcomes.• Administering CD19 CAR T cells to patients without detectable disease is safe, feasible, and warrants further exploration.

[1]  P. Riedell,et al.  Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-cell Lymphomas. , 2022, Transplantation and cellular therapy.

[2]  R. Greil,et al.  Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. , 2021, The New England journal of medicine.

[3]  D. Dingli,et al.  Outpatient practice pattern and remote patient monitoring for axicabtagene ciloleucel CAR-T therapy in patients with aggressive lymphoma. , 2021 .

[4]  S. Schuster,et al.  Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy. , 2021, The New England journal of medicine.

[5]  Zahra Mahmoudjafari,et al.  Chimeric Antigen Receptor T Cell Therapy: A Comprehensive Review of Clinical Efficacy, Toxicity, and Best Practices for Outpatient Administration. , 2021, Transplantation and cellular therapy.

[6]  D. Miklos,et al.  Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. , 2020, Blood advances.

[7]  Michael L. Wang,et al.  Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study , 2020, The Lancet.

[8]  Y. Balagurunathan,et al.  High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. , 2020, Blood advances.

[9]  J. Vose,et al.  Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Bar,et al.  Utilization of Chimeric Antigen Receptor (CAR) T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B cell non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[11]  H. Holte,et al.  Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion. , 2019, Blood advances.

[12]  D. Maloney,et al.  The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. , 2019, Blood.

[13]  S. Grupp,et al.  ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  R. Levy,et al.  Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.

[15]  S. Grupp,et al.  Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. , 2017, Blood.

[16]  A. Zelenetz,et al.  Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. , 2015, Blood.

[17]  Bruce D Cheson,et al.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Vanessa M. Hubbard-Lucey,et al.  Enhanced Responses to Tumor Immunization Following Total Body Irradiation Are Time-Dependent , 2013, PloS one.

[19]  A. LaCasce,et al.  Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era , 2013, British journal of haematology.

[20]  G. Salles,et al.  Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B‐Cell Lymphoma , 2019, The New England journal of medicine.